S��HRN Anal��za rizikov��ch faktorov rozvoja aterosklerotick��ho po��kodenia ciev u os��b s ochoren��m kardiovaskul��rneho syst��mu patr�� k dennej rutine o��etruj��ceho lek��ra, ktor�� individu��lne nastavuje lie��bu s cie��om jej optimaliz��cie pre konkr��tnu rizikov�� osobu. Porucha metabolizmu lipoprote��nov, spojen�� so zv����enou koncentr��ciou cholesterolu, triacylglycerolov a aterog��nnych lipoprote��nov��ch subfrakci��, v����tane mal��ch denzn��ch LDL, je indik��ciou pre lie��bu hypolipidemikami. Lie��ba stat��nmi a fibr��tmi ����inne dok����e zn����i�� koncentr��ciu lipidov a lipoprote��nov v krvi, a t��m zni��i�� kardiovaskul��rne riziko postihnut��ch os��b. Hypolipidemik�� typu stat��ny a fibr��ty ��� ako dokazuj�� aj v��sledky predkladanej klinickej ��t��die ��� m�� st��le prvotn�� miesto v lie��be degenerat��vnych po��koden�� srdca a ciev. Lie��bu stat��nmi je potrebn�� indikova�� pri hypercholesterol��mii pr��padne pri kombinovanej hyperlipo-protein��mii a lie��bu fibr��tmi, v����tane odporu��enia zmeny di��tneho re��imu indikujeme pri zv����enej hladine triacylglycerolov v krvi. ABSTRACT Analysis of risk factors for the development of a degenerative atherosclerotic injury of vessels in subjects with cardiovascular diseases, belongs to the daily routine work of physician, who according to the results adjusts a treatment for everyone risk person individually. An impairment of lipoprotein metabolism characterized by increased concentration of cholesterol, triglycerides, lipoprotein(a) and atherogenic lipoprotein subfractions, including small dense LDLs (sdLDL) in blood, is the indication for treatment with hypolipidemics. Treatment with statins and fibrates is effective in reducing the levels of lipids and lipoproteins in the blood, thereby reducing the risk of people at higher cardiovascular risk. Treatment with statins and fibrates���according to the results of our clinical study���has till now one of the first places in the treatment of degenerative damages of heart and vessels. Statins for treatment of hypercholesterolemia resp.combined hyperlipidemia, and fibrates together with a dietary recommendations there, where the triglycerides become higher.
{"references":["Dukat, A., et al. (2012): Size of low-density lipoprotein particles in patients after stroke. Polskie Archiwum Medycyny Wewnetrznej, 122 (Suppl 1): 30—31. doi: 10.20452/pamw.1491.","Duran, E. K., et al. (2020): Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL, and Incident Cardiovascular Disease. Journal of the American College of Cardiology, 5, 75(17), 2122—2135. doi: 10.1016/j.jacc.2020.02.059.","Hirano, T. (2016): Small dense LDL, HDL 2,3. The Japanese Journal of Clinical Pathology, 64(6), 636—642.","Hirano, T., et al. (2021): Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol. Journal of Atherosclerosis and Thrombosis. doi: 10.5551/jat.62789.","Hirayama, S., Miida, T. (2012): Small dense LDL: An emerging risk factor for cardiovascular disease. Clinica Chimica Acta, 414: 215—224. doi: 10.1016/j.cca.2012.09.010.","Hoefner D. M., et al. (2001):Development of a rapide quantitative method for LDL subfractions with use of the Quantimetrix Lipoprint LDL System. Clinical Chemistry, 472: 266— 274. doi: 10.1093/clinchem/47.2.266.","Hoogeveen, R. C., et al. (2014): Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: The Atherosclerosis Risk In Communities (ARIC) study. Arteriosclerosis, Thrombosis, and Vascular Biology, 34: 1069—1077. doi: 10.1161/ATVBAHA.114.303284","Ikezaki, H., et al. (2021): Small Dense Low-Density Lipoprotrein Cholesterol is the most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study. Journal of the American Heart Association, 10(5), e019140. doi: 10.1161/jaha.120.019140.","Johannesen, C. D. L., et al. (2021): Apolipoprotein B and Non-HDL Cholesterol Better Reflec Residual Risk Than LDL Cholesterol in Statin-Treated Patients. Journal of American College of Cardiology, 2021, 77(11), 1439—1450.","Kasko, M., et al. (2014): High density lipoprotein profile in newly-diagnosed lower extremity artery disease in Slovak population without diabetes mellitus. Neuroendocrinology Letters, 35(6): 531—537.","Kasko, M., Kasko, V., Oravec, S. (2018): Would Janus' view on HDL be useful? Bratislava Medical Journal, 119(4): 245— 248. doi: 10.4149/BLL_2018_046.","Katsiki, N. (2013): The Role of Fibrate Treatment in Dyslipidemia: An Overview. Current Pharmaceutical Design, 19(17): 3124—31. doi: 10.2174/1381612811319170020","Komyia, I. (2021): Pemafibrate decreases small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: An observation study. Lipids in Health and Disease, 20(1). doi: 10.1186/s12944-021-01434-8.","Mach, F., Baigent, C., Catapano, A. L., et al., ESC Scientific Document Grup (2020): 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur. Heart, J., 41(1): 111—188. doi: 190. 1093/eurheartj/ehz 455.","Morais, J., Neyer, G., Muniz, N. (2003): Measurement and Distribution of HDL subclasses with the new Lipoprint HDL. Method. Abstract of the 55th Annual Meeting of the AACC, Philadelphia, Pennsylvania, USA, July 20—24, 2003.","Okopien, B., et al. (2017): Fibrates in the management of Laboratórna diagnostika 2/2021 73 atherogenic dyslipidemi Expert Review. Cardiovascular Therapy, 15(12), 913—921. doi: 10.1080/14779072.2017.1408410.","Okopien B., et al. (2018): Benefits and risks of the treatment with fibrates—a comprehensive summary. Expert Rev. Clinical Pharmacology, 11(11): 1099—1112. doi: 10.1080/17512433. 2018.1537780.","Oravec, S., et al. (2014): Atherogenic versus non-atherogenic lipoprotein profiles in healthy individuals. Is there a need to change an approach to diagnosing dyslipidemia ? Current Medical Chemistry, 21: 2892—2901. doi: 10.2174/0929867321666 140303153048.","Oravec, S., et al. (2015): The Assesment of the Atherogenic Lipoprotein profile in Cardovascular Diseases by Lipoprint System Analysis. In Lipoproteins—from Bench to Bedside, edited by Gerhard Kostner and Indumathi Chennamesetty, InTech, 87-11121. doi: 10.5772/60989.","Oravec, S., et al. (2019): Small dense LDL—an important part of the lipoprotein profile in individuals with impaired metabolism of lipoproteins. Comparison of two analytical procedures. Neuroendocrinology Letters, 40(4): 195—198.","Oravec, S., et al. (2020): Malé denzné LDL u osôb s poruchou metabolizmu lipoproteínov. Laboratórna Diagnostika, 25(2) pp. 43—46.","Rosenblit, P. D. (2019): Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at Extreme ASCVD Risk. Current Diabetic Rep., 21: 19(12): 146. doi: 10.1007/ s11892-019-1246-y","Sampson, M., et al. (2021): A New Equation Based on the Standard Lipid Panel for Calculating small Dense Low-Density Lipoprotein-Cholesterol and Its Use as a Risk-Enhancer Test. Clinical Chemistry, 67:(7), 987—997. doi: 10.1093/clin chem/048.","Tenenbaum, A., Fishman, E. Z. (2012): Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc. Diabetol., 2012: 11:125. doi: 10.1186/1475-2840-11-125.","Toth, P. P. (2016): Triglyceride-rich lipoproteins as a causal factor for cardiovascular diesase. Vascular Health and Risk Management, 12: 171—83. doi: 10.2147/VHRM.S104369.","Vallejo-Vaz, A. J. (2018): Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 2018, 21:138(8), 770—781. doi: 10.1161/CIRCULATIONAHA,117.032318.","Watts, G. F. Chan, D. C. (2020): Atherogenic Dyslipoproteinemia and Management of ASCVD: Will New Indices Untie the Gordon Knot? J. American College of Cardiology, 75(17), 2136—2139. doi: 10.1016/jacc.2020.03.032."]}